Patent ID: 8329676

Claim:
A method for treatment of a pathological condition or symptom in a mammal, wherein the activity of sphingosine 1-phosphate receptors is implicated and agonism of such activity is desired, comprising administering to said mammal an effective amount of a compound having the formula: wherein R 4 and R 7 are independently CH, or CH 2 ; R 5 is C, CH, or N, R 6 is CH, CH 2 , O, S or NR 3 ; wherein R 3 is hydrogen, or an (C 1 -C 10 ) alkyl group; X is selected from hydroxyl, phosphate, phosphonate, alpha-substituted phosphonate; R 1 is selected from the group consisting of hydrogen, halo, trifluoromethyl, (C 1 -C 10 ) alkyl, (C 1 -C 10 ) alkyl substituted with halo, hydroxy-, (C 1 -C 10 ) alkoxy, or cyano; and R 2 is selected from the group consisting of (C 1 -C 10 )alkyl, cycloalkyl substituted alkyl, (C 2 -C 20 )alkenyl, (C 2 -C 20 )alkynyl, aryl, alkyl substituted aryl, arylalkyl and aryl substituted arylalkyl; wherein one or more of the carbon atoms in the R 2 groups can be independently replaced with non-peroxide oxygen, sulfur or NR 8 ; wherein R 8 is hydrogen, or an (C 1 -C 10 ) alkyl group; wherein the alkyl, alkenyl, and alkynyl groups in R 2 are optionally substituted with oxo; n is 0, 1, 2 or 3; and represents 1,2, or 3, optional double bonds; or a pharmaceutically acceptable salt or ester thereof, wherein the treatment of the pathological condition or symptom comprises altering lymphocyte trafficking.